View Press Releases
PSI Expands Toronto Operations with New Office and Appoints David Allen as Canada Country Manager
PSI CRO, a Swiss-based contract research organization, has expanded its Toronto operations with the opening of a new office location in Ontario. The expansion builds on PSI’s long-standing presence in the Canadian clinical trial market, where the company is known for disciplined start-up execution, strong site partnerships, and predictable patient enrollment. PSI has been active in Canada for more than a decade, steadily growing its footprint by supporting complex trials with delivery-focused teams and consistent operational performance. The new office is located at 5015 Spectrum Way, Suite 410, Mississauga, Ontario, L4W 0E4.
As part of this expansion, PSI has appointed David Allen, MBA, as Country Manager for Canada. Allen brings over 30 years of experience in clinical research across both sponsor and CRO environments. Throughout his career, he has been recognized for building stable, accountable teams and translating operational plans into reliable trial execution. In this role, Allen will focus on strengthening PSI’s Canadian delivery organization in line with the company’s global on-time performance standards.
“I am excited to join PSI as it marks its 30th anniversary of advancing medicine in close partnership with sites, sponsors, and vendors worldwide,” said Allen. “Canada has a mature clinical research ecosystem and a strong investigator community. That combination is well suited to PSI’s delivery model, particularly for pivotal trials where timelines matter and execution discipline is critical. I look forward to supporting sponsors as they navigate increasingly complex development programs.”
“Opening a new office in Toronto reflects PSI’s long-term commitment to Canada as a strategic trial location,” said Tibor Kovacs, Head of North America, PSI. “David’s experience and leadership style align closely with how we operate — building dependable local teams that integrate seamlessly into global programs and deliver studies on time.”
With North America continuing to lead in the number of clinical trials and sites initiated in 2025, PSI’s growth in Canada further strengthens its ability to support sponsors running pivotal trials across the region and globally, particularly in indications requiring experienced sites and tight operational control.
To learn more about PSI’s capabilities in Canada, please contact us today.
ENDS
For further information, please contact:
PSI
Ashley Collins
E: ashley.stufanocollins@psi-cro.com
Sciad Communications, Media Relations
Jasmin Shearan, Maria Taylor
Notes for Editors
About PSI
PSI CRO is a global, full-service contract research organization (CRO) focused on the disciplined delivery of pivotal clinical trials. The company’s defining operational metric is on-time trial delivery, which has consistently remained above 90% in 2025 — reflecting the strength of its teams, processes, and site relationships.
PSI specializes in phase II and phase III clinical trials in oncology, hematology, gastroenterology, autoimmune diseases, infectious diseases, neurology, and other complex indications. The company is particularly experienced in trials requiring advanced operational coordination, including platform and umbrella designs, targeted immunotherapies, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI celebrated its 30th year as the only fully independent and privately owned mid-sized CRO. The company employs over 3,200 professionals across 56 countries as of December 19, 2025. PSI’s global headquarters are located in Zug, Switzerland.
For more information, visit www.psi-cro.com.